New combo therapy targets abdominal cancer spread in early trial
NCT ID NCT07453875
First seen Mar 07, 2026 · Last updated May 13, 2026 · Updated 7 times
Summary
This early-phase study tests whether low-dose radiation to the whole abdomen, followed by a special chemotherapy given into the belly and an immunotherapy drug, is safe and works for people with stomach or colorectal cancer that has spread to the lining of the abdomen. About 9 to 18 participants will receive this treatment at one hospital in China. The main goal is to check for side effects and see if the treatment can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LDRT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Army Medical Center
Chongqing, Chongqing Municipality, 400042, China
-
Daping Hospital, Army Medical University
Chongqing, Chongqing Municipality, 400042, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.